• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates.

作者信息

Woodle E Steve, Tremblay Simon, Driscoll James

机构信息

Division of Transplantation, Department of Surgery, and

Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.

出版信息

J Am Soc Nephrol. 2017 Jul;28(7):1951-1953. doi: 10.1681/ASN.2017040443. Epub 2017 Jun 7.

DOI:10.1681/ASN.2017040443
PMID:28592425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5491302/
Abstract
摘要

相似文献

1
Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates.用蛋白酶体抑制剂靶向浆细胞：来自灵长类动物的原理
J Am Soc Nephrol. 2017 Jul;28(7):1951-1953. doi: 10.1681/ASN.2017040443. Epub 2017 Jun 7.
2
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.硼替佐米对蛋白酶体的抑制作用：对致敏患者肾移植等待期 HLA 抗体水平和特异性的影响。
Transpl Immunol. 2012 Jun;26(4):171-5. doi: 10.1016/j.trim.2012.01.002. Epub 2012 Feb 2.
3
Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.蛋白酶体抑制可减少小鼠的同种异体抗体分泌浆细胞和供体特异性抗体。
Transpl Immunol. 2013 Dec;29(1-4):11-6. doi: 10.1016/j.trim.2013.09.010. Epub 2013 Oct 5.
4
Proteasome inhibition for antibody-mediated rejection.蛋白酶体抑制治疗抗体介导的排斥反应。
Curr Opin Organ Transplant. 2009 Dec;14(6):662-6. doi: 10.1097/MOT.0b013e328330f304.
5
Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.硼替佐米用于肾移植受者难治性急性抗体介导排斥反应：一项单中心病例系列研究。
Nephrology (Carlton). 2016 Aug;21(8):700-4. doi: 10.1111/nep.12659.
6
Differential effect of bortezomib on HLA class I and class II antibody.硼替佐米对 HLA Ⅰ类和Ⅱ类抗体的差异作用。
Transplantation. 2014 Sep 27;98(6):660-5. doi: 10.1097/TP.0000000000000132.
7
HLA desensitization with bortezomib in a highly sensitized pediatric patient.在一名高度致敏的儿科患者中使用硼替佐米进行HLA脱敏治疗。
Pediatr Transplant. 2014 Dec;18(8):E280-2. doi: 10.1111/petr.12347. Epub 2014 Sep 1.
8
Proteasome inhibitor treatment of antibody-mediated allograft rejection.蛋白酶体抑制剂治疗抗体介导的移植物排斥反应。
Curr Opin Organ Transplant. 2011 Aug;16(4):434-8. doi: 10.1097/MOT.0b013e328348c0e5.
9
Bortezomib in Kidney Transplant: Current Use and Perspectives.硼替佐米在肾移植中的应用：现状和展望。
Curr Drug Metab. 2017;18(12):1136-1146. doi: 10.2174/1389200218666171121100716.
10
Proteasome inhibitor therapy for antibody-mediated rejection.蛋白酶体抑制剂疗法用于抗体介导的排斥反应。
Pediatr Transplant. 2011 Sep;15(6):548-56. doi: 10.1111/j.1399-3046.2011.01543.x.

引用本文的文献

1
Bone marrow plasma cells require P2RX4 to sense extracellular ATP.骨髓浆细胞需要 P2RX4 来感知细胞外 ATP。
Nature. 2024 Feb;626(8001):1102-1107. doi: 10.1038/s41586-024-07047-2. Epub 2024 Feb 14.
2
The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.蛋白酶体抑制剂硼替佐米诱导激活 B 细胞中的 p53 依赖性细胞凋亡。
J Immunol. 2024 Jan 1;212(1):154-164. doi: 10.4049/jimmunol.2300212.
3
Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes.靶向蛋白酶体治疗癌症和感染性疾病：一种治疗恶性肿瘤和微生物的并行策略。
Front Cell Infect Microbiol. 2022 Jul 7;12:925804. doi: 10.3389/fcimb.2022.925804. eCollection 2022.
4
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.类风湿关节炎发病机制的最新研究进展：新的治疗策略。
Cells. 2021 Nov 4;10(11):3017. doi: 10.3390/cells10113017.
5
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.新兴的脱敏新方法：针对 HLA 致敏的靶向治疗。
Front Immunol. 2021 Jun 11;12:694763. doi: 10.3389/fimmu.2021.694763. eCollection 2021.
6
Therapies for Chronic Allograft Rejection.慢性移植物排斥反应的治疗方法。
Front Pharmacol. 2021 Apr 15;12:651222. doi: 10.3389/fphar.2021.651222. eCollection 2021.
7
Experimental modeling of desensitization: What have we learned about preventing AMR?脱敏的实验建模：我们从中学到了哪些预防 AMR 的知识？
Am J Transplant. 2020 Jun;20 Suppl 4(Suppl 4):2-11. doi: 10.1111/ajt.15873.
8
Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study.肾移植受者慢性活动性抗体介导的排斥反应的治疗-单中心回顾性研究。
BMC Nephrol. 2020 Jan 6;21(1):6. doi: 10.1186/s12882-019-1672-8.
9
Non-classical B Cell Memory of Allergic IgE Responses.非经典 B 细胞记忆在过敏 IgE 应答中的作用。
Front Immunol. 2019 Apr 26;10:715. doi: 10.3389/fimmu.2019.00715. eCollection 2019.
10
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.硼替佐米治疗晚期抗体介导的肾移植排斥反应的随机临床试验。
J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.

本文引用的文献

1
Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients.硼替佐米治疗致敏受者后的体液补偿
J Am Soc Nephrol. 2017 Jul;28(7):1991-1996. doi: 10.1681/ASN.2016070727. Epub 2017 Feb 23.
2
Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology.致敏非人灵长类动物中的抗体介导排斥反应：人类生物学建模
Am J Transplant. 2016 Jun;16(6):1726-38. doi: 10.1111/ajt.13688. Epub 2016 Mar 25.
3
Prospective iterative trial of proteasome inhibitor-based desensitization.基于蛋白酶体抑制剂的脱敏前瞻性迭代试验。
Am J Transplant. 2015 Jan;15(1):101-18. doi: 10.1111/ajt.13050.
4
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.一种针对蛋白酶体泛素受体 RPN13/ADRM1 的双苄叉哌啶酮，可作为癌症的治疗方法。
Cancer Cell. 2013 Dec 9;24(6):791-805. doi: 10.1016/j.ccr.2013.11.001.
5
Proteasome inhibitor therapy for antibody-mediated rejection.蛋白酶体抑制剂疗法用于抗体介导的排斥反应。
Pediatr Transplant. 2011 Sep;15(6):548-56. doi: 10.1111/j.1399-3046.2011.01543.x.
6
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.蛋白酶体抑制作用会加重炎性关节炎小鼠模型中肿瘤坏死因子介导的骨吸收。
Arthritis Rheum. 2011 Mar;63(3):670-80. doi: 10.1002/art.30177.
7
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.在实验性自身免疫性重症肌无力中，用硼替佐米抑制蛋白酶体可减少浆细胞和自身抗体。
J Immunol. 2011 Feb 15;186(4):2503-13. doi: 10.4049/jimmunol.1002539. Epub 2011 Jan 14.
8
Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.硼替佐米对髓过氧化物酶特异性浆细胞的清除作用可预防抗中性粒细胞胞浆自身抗体诱导的肾小球肾炎。
J Am Soc Nephrol. 2011 Feb;22(2):336-48. doi: 10.1681/ASN.2010010034. Epub 2011 Jan 13.
9
Plasma cells negatively regulate the follicular helper T cell program.浆细胞负向调控滤泡辅助性 T 细胞程序。
Nat Immunol. 2010 Dec;11(12):1110-8. doi: 10.1038/ni.1954. Epub 2010 Oct 31.
10
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.蛋白酶体抑制剂硼替佐米对大鼠佐剂诱导性关节炎中的炎症和骨病有显著影响。
Arthritis Rheum. 2010 Nov;62(11):3277-88. doi: 10.1002/art.27690.